Michael J. McKenna, PhD, Non-Executive Chairman
Michael served as Chairman from February 2008 to February 2009, as Merrion's Chief Executive Officer from April 2004 to February 2008, and on the board of directors since April 2004. From September 1999 to March 2004, Michael served as vice president of science and technology at A.M. Pappas & Associates, LLC, a life sciences venture development company. Previously, he owned and operated Pharmaceutical Consulting Services, advising the biopharmaceutical industry in drug development and drug safety. Prior to this he was Vice President, Drug Development at Parke Davis. Michael also held numerous scientific and managerial positions in the toxicology laboratories of The Dow Chemical Company and Parke Davis. Michael received a B.A. in English from St. John Fisher College and a PhD in Toxicology from the University of Rochester School of Medicine and Dentistry.
|Member of the Compensation Committee|
John S. Fox, PhD, Chief Executive Officer
John joined Merrion in 2008 as Chief Development Officer. Prior to joining Merrion, John was Chief Operating Officer of Hunter Fleming, a company he co-founded in 1999 to develop early stage projects derived from University research and focussed on neuroprotection. Hunter Fleming was subsequently acquired by Newron Pharmaceuticals SpA. John has spent over 25 years in the pharmaceutical industry in a variety of pharmaceutical development and operational roles and has experience of both SME and multinational companies. Prior to setting up Hunter Fleming he was Head of the Clinical Research Coordination Group in the UK affiliate of Eli Lilly & Co. and later Director of Planning for Shire Pharmaceuticals. He has also held non-executive Board roles with the technology transfer company of the University of Southampton, Southampton Asset Management Ltd., and until recently as Chairman of Endocrine Pharmaceuticals Ltd. John holds a BSc and PhD in Biochemistry from Queens University Belfast and an MBA from Henley Management College.
Harry Stratford, Non-Executive and Chair of the Compensation, Nominating and Governance Committee
Harry is the founder and executive chairman of Stratford Healthcare founded in 2008. Harry has over 36 years experience in the pharmaceutical industry. He has built two successful publicly listed pharmaceutical companies from the ground up. Prior to Stratford Healthcare's foundation, Harry was the founder, CEO and Executive Chairman of Prostrakan Plc, the UK International specialty pharmaceutical company. He founded Shire Pharmaceuticals in 1986 and was CEO for almost a decade. Harry holds a BSc. in Chemistry from the University of London and was awarded an OBE in 2007 New Year's Honours list for his contribution to the Scottish Life Sciences Industry. Harry is also a Non-Executive Director of Consilient Health Ltd.
|Chair of the Nominating and Governance Committee|
|Chair of the Compensation Committee|
Fintan Maher, Non-Executive
National Head of Private Wealth for the Myer Family Company, the largest multi-family-office in Australia. Fintan joined the Myer Family Company in January 2012, following a previous position as a Head of Family Office at Macquarie Bank. From late 2004-2010 he was CEO of Growcorp Group, a Life Science Venture Capital Fund based in Ireland. Prior to that he spent 5 years as Chief Investment Officer with Irelandia Investments, the family office for the Ryan family based in Ireland. He began his career as a Fund Manager based in NY managing a multi-billion bond portfolio. He has 25 years financial experience, covering the investment markets, capital raising, IPO's, private equity investments and private wealth management. He is also a founding director of Merrion Pharmaceuticals.
|Member of the Audit Committee|
Gerard Flood, Non-Executive
Gerard was until 2009 a Partner in the KPMG Irish Practice for 25 years and Chairman of its Corporate Finance Division. Throughout his career, Gerard advised Public and Private Companies, State and Semi-State organisations in Merger and Acquisition activity, Fund raising, Project Finance, Corporate and Financial structuring and Strategy determination. Gerard was also an executive member of the KPMG Corporate Finance, Europe, Middle East and Africa Board which focused on the development of KPMG's involvement in cross border M&A and Project Finance assignments.
|Chair of the Audit Committee|
|Member of the Nominating and Governance Committee|
|Member of the Compensation Committee|